Tarsus Pharmaceuticals, Inc. Common Stock
TARS Real Time Price USDRecent trades of TARS by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by TARS's directors and management
Government lobbying spending instances
Estimated quarterly lobbying spending
New patents grants
-
Patent Title: Ophthalmic compositions for treating ocular Sep. 12, 2023
-
Patent Title: Methods for treating ocular Jul. 04, 2023
-
Patent Title: Methods for treating demodex blepharitis using lotilaner formulations Jul. 04, 2023
-
Patent Title: Isoxazoline parasiticide formulations and methods for treating blepharitis Dec. 14, 2021
-
Patent Title: Methods for treating ocular demodex using isoxazoline parasiticide formulations Nov. 17, 2020
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Number of mentions of TARS in WallStreetBets Daily Discussion
Recent insights relating to TARS
Recent picks made for TARS stock on CNBC
ETFs with the largest estimated holdings in TARS
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view TARS Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.